Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Eisai’s Oral Solid Dose Facility Completed in China
January 12, 2018
- Nippon Chemiphar’s Antidepressant Candidate Selected for AMED’s CiCLE Grant Program
January 12, 2018
- Suglat Filed for Type 1 Diabetes in Japan: Astellas/Kotobuki
January 12, 2018
- Will Symbicort and Adoair Face Generic Entries This Year? Trade Group Has Seen High Hurdle for Inhaler Drugs
January 11, 2018
- DeNA in AI Joint Research Pact with Asahi Kasei, Shionogi
January 11, 2018
- Shionogi Gains Access to US Startup’s Drug Discovery Platform
January 11, 2018
- Talion Authorized Generics to Launch on March 1
January 11, 2018
- Genentech Seeks to Block Rituxan Biosimilar Launch in Japan
January 10, 2018
- Lenvima-Keytruda Combo Earns FDA’s Breakthrough Designation for RCC
January 10, 2018
- GSK Canada Head Tapped for Japan President
January 10, 2018
- ALL Med Blinatumomab Filed in Japan: Amgen Astellas
January 10, 2018
- Takeda Snaps Up Cell Therapy Partner TiGenix in GI, Partners with Denali in CNS
January 9, 2018
- Chugai Executes Asset Transfer for 13 Off-Patent Brands
January 9, 2018
- Will Pricing Reform Spur Divestment of Off-Patent Brands in Japan? Next 3 Months Hold Key for Future Directions
January 1, 2018
- Nissui Pharma to Invest in Keio Univ. Spinoff Specializing in Saliva-Based Tests
December 28, 2017
- China FDA Puts Lenvima on Priority Review for HCC
December 28, 2017
- Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med
December 28, 2017
- Generic Use Rate at 68.8% in July-September: JGA
December 27, 2017
- Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec
December 27, 2017
- Otsuka Group to Invest 1 Billion Yen in Kyoto Startup, Aims to Commercialize iPS Cell-Derived Platelets
December 26, 2017
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…